Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16084902 | 0.83 | TP53 (0.39) | KMT2AALDH1A1NFE2L2 | |
| SCHEMBL21144249 | 0.77 | TRPV4 (0.44) | TRPV4ALDH1A1 | |
| SCHEMBL29354194 | 0.77 | TRPV4 (0.44) | TRPV4ALDH1A1 | |
| SCHEMBL1816343 | 0.77 | NFE2L2 (0.51) | LMNAPKMHTTNFE2L2 | |
| SCHEMBL14650818 | 0.76 | PPARD (0.41) | KMT2AMEN1RAB9AALDH1A1NFE2L2 | |
| SCHEMBL856562 | 0.76 | TRPV4 (0.46) | TRPV4KMT2AMEN1AGTR1RAB9A | |
| SCHEMBL16085032 | 0.74 | NQO1 (0.45) | KMT2ARAB9ALMNAALDH1A1PKM | |
| SCHEMBL30435013 | 0.72 | NFE2L2 (0.42) | PKMHTTNFE2L2 | |
| SCHEMBL29433330 | 0.72 | CHRNA3 (0.41) | KMT2ALMNA | |
| SCHEMBL15738713 | 0.72 | CHRNA3 (0.41) | KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| WO-2024245143-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | 赛诺哈勃药业（成都）有限公司 | 2024-12-05 | — | — | WO | disclosed |
| EP-4455136-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| CN-118510768-A | Diazasulfinyl structure-containing compounds and their use in medicine | 赛诺哈勃药业（成都）有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024137865-A1 | COMPOUNDS USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116774-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | 赛诺哈勃药业（成都）有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116774-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | 赛诺哈勃药业（成都）有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| WO-2018055524-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | TRPV4 4426/4885KMT2A 646/4885MEN1 1775/4885 |
| US-11229623-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885KMT2A 3648/4885MEN1 4667/4885 |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885KMT2A 3648/4885MEN1 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.